Nutriband (NTRB)
Develops transdermal drug products centered on its AVERSA abuse-deterrent patch technology.
Something off on this page? Send us feedback.
Develops transdermal pharmaceutical products through its 4P Therapeutics drug-development business, with AVERSA as the core technology. AVERSA is designed for existing drug patches that can be abused or misused, and AVERSA Fentanyl is the lead program in development.
Develops a portfolio of transdermal pharmaceutical products, with its pipeline principally based on AVERSA, a proprietary abuse-deterrent technology for drug patches that can be abused or misused. The 4P Therapeutics drug-development business became its principal business after the 2018 acquisition, shifting the focus from consumer transdermal products marketed outside the United States. AVERSA Fentanyl is the lead development program.
Founded as Nutriband Ltd. in Ireland, the organization now operates through a Nevada parent headquartered in Orlando, Florida and led by CEO Gareth Sheridan. Common stock has traded on Nasdaq since 2021. AVERSA Fentanyl remains a development-stage product; marketing depends on its development program, including preclinical and clinical trials, and FDA approval.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $3.4M · Total debt $194.6K · Total assets $6.3M · Shareholders' equity $5.3M
- Revenue
- $437.5K
- Operating income
- −$890.6K
- Net income
- −$880.6K
No dividends on record.
| Institutions | 2.90% | 352.3K shares | |
|---|---|---|---|
| 16 holders · as of Jun 30, 2026 | |||
| Insiders | 23.51% | 2.86M shares | |
| 2 holders · as of Sep 15, 2026 | |||
| Other | 73.59% | 8.95M shares | |
| remainder | |||
12.16M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Gareth SheridanInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 14.69% | 1.79M | filed Sep 15, 2026 |
Serguei Melnik1Insiderdirector, 10 percent owner, officer: Chairman and President | 8.81% | 1.07M | filed Mar 13, 2025 |
Vanguard Capital Management LLCInstitution | 1.44% | 174,927 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.51% | 62,494 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.21% | 25,111 | as of Jun 30, 2026 |
- Serguei Melnik's transaction reports restate only vehicles that traded; the 2025 ownership statement (1.07M) is used instead.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Viatris
Marketed generic fentanyl patch for long-term, around-the-clock pain
- Teva (ADR)
Marketed fentanyl patches for continuous 72-hour opioid delivery
- Scilex
Prescription pain topical-system franchise built around ZTlido
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nutriband | $6.85 | −1.44% | $94.5M | — | — | 58.4 | −29.7% |
| Viatris | $17.00 | −1.05% | $19.91B | — | 6.7 | 1.4 | +4.9% |
| Teva (ADR) | $39.33 | −0.41% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Scilex | $5.36 | −0.06% | $43.8M | — | 57.4 | 1.4 | −22.8% |
| Median | 66.8 | 14.1 | 1.4 | −0.8% |